AxoGen price target raised to $17 from $15 at Canaccord

Canaccord raised the firm’s price target on AxoGen to $17 from $15 and keeps a Buy rating on the shares. The firm said they posted strong Q2 results, beating street expectations on both the top and bottom lines and raising its FY24 revenue guidance.